BioCentury
ARTICLE | Clinical News

Loxo reports Phase I RET inhibitor data

May 18, 2018 7:11 PM UTC

Loxo Oncology Inc. (NASDAQ:LOXO) reported response data from an open-label, international Phase I trial of its ret proto-oncogene (RET) inhibitor LOXO-292 to treat RET-altered cancers. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

In 32 evaluable patients with RET fusion-positive tumors, oral LOXO-292 led to an overall response rate (ORR) of 69%, including an ORR of 65% in 26 non-small cell lung cancer (NSCLC) patients and 83% in six papillary thyroid cancer patients. Additionally, 84% of patients had radiographic tumor reductions of 19-67%...